Rising Fungus Cases in Healthcare Facilities: What You Need to Know

Healthcare facilities across the United States face a growing challenge as clinical cases of the multidrug-resistant yeast Candida auris surge, with the US Centers for Disease Control and Prevention recording 3,437 clinical cases across 27 states as of July 25, according to recent federal data. First detected in Japan in 2009 and subsequently identified in the US in 2016, the pathogen remains classified as an urgent public health threat due to its persistence on environmental surfaces and resistance to standard antifungal treatments.

Understanding Candida Auris Transmission in Medical Facilities

The organism spreads primarily through contact with contaminated individuals and objects within healthcare settings, according to Dr. Graham Snyder, medical director of infection prevention and hospital epidemiology at University of Pittsburgh Medical Center. Unlike many other germs, the yeast demonstrates an exceptional ability to persist in hospital and nursing home environments because it can survive certain cleaning products. Dr. Snyder notes that infection prevention teams must apply specialized disinfection measures whenever a patient tests positive for the pathogen. Dr. Scott Roberts, an associate professor of infection prevention at Yale University, explains that the yeast can colonize a person’s skin asymptomatically, typically detected via an armpit or groin swab, or it can develop into a true infection if it enters the bloodstream through breaks in the skin, particularly among individuals with compromised immune systems.

Clinical Symptoms and Vulnerable Patient Populations

When the yeast breaches the skin and enters the bloodstream, it can cause severe clinical manifestations, including fever, low blood pressure, high heart rate, and life-threatening sepsis, according to Dr. Ilan Schwartz, an associate professor of medicine at Duke University. Because the pathogen circulates predominantly inside medical facilities, it primarily threatens vulnerable patients already receiving treatment for underlying health conditions. Individuals undergoing chemotherapy, recovering from recent surgeries, or taking antibiotics face the highest risk of developing severe infections. Dr. Nitipong Permpalung, director of mycology research at Johns Hopkins University, emphasizes that clinicians must carefully differentiate between patients who are merely colonized on the skin and those experiencing active clinical infections to ensure proper patient care and data tracking.

Prevention Strategies and Hospital Screening Challenges

Managing the spread of the fungus relies heavily on rigorous hand hygiene, strict disinfection of medical equipment before use, and transparent communication among care teams and family members, according to Dr. Roberts. Dr. Roberts points out that many medical facilities lack the laboratory infrastructure or funding to test for the pathogen routinely, making it difficult to gauge the true scope of the issue. When colonization occurs, medical management generally focuses on monitoring for symptoms and increasing environmental awareness in patient rooms, as specific treatment options for colonization are limited.

Frequently Asked Questions

What is Candida auris?

Candida auris is a specific type of yeast and fungus that can cause severe infections in hospitalized patients and exhibits resistance to multiple classes of antifungal medications, according to the CDC.

How does Candida auris spread?

The pathogen spreads through contact with infected individuals or contaminated surfaces in healthcare settings such as hospitals and nursing homes, where it can linger despite routine cleaning efforts, according to Dr. Graham Snyder.

What are the symptoms of a Candida auris infection?

Symptoms include fever, high heart rate, low blood pressure, and sepsis if the yeast enters the bloodstream through breaks in the skin, according to Dr. Ilan Schwartz.

Who is most at risk of severe illness?